Spero Therapeutics (NASDAQ:SPRO) Research Coverage Started at Cantor Fitzgerald

Posted by George Bondi on Oct 31st, 2026

Cantor Fitzgerald initiated coverage on shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) in a research note released on Wednesday, Marketbeat reports. The firm issued an overweight rating and a $6.00 price objective on the stock.

A number of other research firms also recently issued reports on SPRO. Compass Point upgraded Spero Therapeutics to a “neutral” rating in a research note on Monday, September 14th. Weiss Ratings downgraded Spero Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday. Zacks Research upgraded Spero Therapeutics to a “hold” rating in a report on Monday, September 14th. Finally, HC Wainwright lifted their target price on Spero Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Monday, September 14th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Read Our Latest Report on SPRO

Spero Therapeutics Trading Down 4.5%

Spero Therapeutics stock opened at $1.06 on Wednesday. Spero Therapeutics has a 1-year low of $1.04 and a 1-year high of $3.08. The firm has a market capitalization of $61.73 million, a price-to-earnings ratio of 9.64 and a beta of 1.50. The firm’s fifty day moving average price is $1.17 and its two-hundred day moving average price is $1.98.

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%. On average, research analysts forecast that Spero Therapeutics will post -0.97 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC bought a new stake in Spero Therapeutics in the second quarter worth about $36,000. Global Retirement Partners LLC purchased a new position in Spero Therapeutics in the second quarter valued at about $55,000. GSA Capital Partners LLP purchased a new position in Spero Therapeutics in the second quarter valued at about $632,000. BlackRock Inc. bought a new position in shares of Spero Therapeutics during the 2nd quarter valued at approximately $1,314,000. Finally, Alphabet Inc. bought a new position in shares of Spero Therapeutics during the 2nd quarter valued at approximately $1,967,000. 25.60% of the stock is currently owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

(Get Free Report)

Spero Therapeutics, Inc (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens.

Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.